HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.7%

Neg 0% Neu 89.7% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.